Glucose-6-phosphate dehydrogenase (G6PD) deficiency

Last updated: November 01, 2022

Glucose-6-phosphate dehydrogenase (G6PD) deficiency

DMPR

DMPR

Chiari malformation
Syringomyelia
Ischemic stroke
Intracerebral hemorrhage
Epidural hematoma
Subarachnoid hemorrhage
Subdural hematoma
Arteriovenous malformation
Wernicke-Korsakoff syndrome
Broca aphasia
Wernicke aphasia
Concussion and traumatic brain injury
Seizures and epilepsy
Febrile seizure
Tension headache
Cluster headache
Migraine
Alzheimer disease
Vascular dementia
Dementia with Lewy bodies
Frontotemporal dementia
Normal pressure hydrocephalus
Creutzfeldt-Jakob disease
Parkinson disease
Huntington disease
Multiple sclerosis
Central pontine myelinolysis
Transverse myelitis
Acute disseminated encephalomyelitis
JC virus (Progressive multifocal leukoencephalopathy)
Adult brain tumors
Pituitary adenoma
Pediatric brain tumors
Acoustic neuroma (schwannoma)
Brain herniation
Brown-Sequard Syndrome
Cauda equina syndrome
Vitamin B12 deficiency
Friedreich ataxia
Treponema pallidum (Syphilis)
Meningitis
Sturge-Weber syndrome
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Spinal muscular atrophy
Poliovirus
Charcot-Marie-Tooth disease
Guillain-Barre syndrome
Bell palsy
Carpal tunnel syndrome
Erb-Duchenne palsy
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Horner syndrome
Orthostatic hypotension
Congenital neurological disorders: Pathology review
Headaches: Pathology review
Seizures: Pathology review
Cerebral vascular disease: Pathology review
Traumatic brain injury: Pathology review
Spinal cord disorders: Pathology review
Dementia: Pathology review
Central nervous system infections: Pathology review
Movement disorders: Pathology review
Neuromuscular junction disorders: Pathology review
Demyelinating disorders: Pathology review
Adult brain tumors: Pathology review
Pediatric brain tumors: Pathology review
Neurocutaneous disorders: Pathology review
Hyperphosphatemia
Hypophosphatemia
Hyponatremia
Hypernatremia
Hypermagnesemia
Hypomagnesemia
Hypokalemia
Hyperkalemia
Hypercalcemia
Hypocalcemia
Renal tubular acidosis
Diabetic nephropathy
Lupus nephritis
Membranoproliferative glomerulonephritis
Membranous nephropathy
IgA nephropathy (NORD)
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Acid-base disturbances: Pathology review
Electrolyte disturbances: Pathology review
Retinoblastoma
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemolytic-uremic syndrome
Antiphospholipid syndrome
Complement deficiency
Vitiligo
Albinism
Bone tumors
Osteochondroma
Chondrosarcoma
Osteomalacia and rickets
Paget disease of bone
Osteoporosis
Osteosclerosis
Muscular dystrophy
Polymyositis
Dermatomyositis
Inclusion body myopathy
Polymyalgia rheumatica
Sjogren syndrome
Rett syndrome

Transcript

Watch video only

Glucose-6-phosphate dehydrogenase deficiency, or G6PD deficiency, is a genetic disorder characterized by decreased levels of glucose-6-phosphate dehydrogenase, which leads to the destruction of red blood cells.

Normally, as a part of the metabolic process, our body produces free radicals like hydrogen peroxide, or H2O2.

Free radicals can damage the cells in many ways including destroying the DNA, proteins, and the cell membrane.

Now, we have a molecule in our body called glutathione which acts as an antioxidant and goes around and neutralizes these free radicals.

In order to function, these molecules need to be in the reduced state where they can donate an electron to the H2O2 and convert them into harmless water and oxygen.

However this causes the glutathione to become oxidized, so before it can get back to work, an enzyme called glutathione reductase will use an NADPH as an electron donor and and reduce the oxidized glutathione back into its working state.

After giving up its electron, the NADPH will become NADP+.

So to replenish the supply of NADPH, we have the glucose-6-phosphate dehydrogenase enzyme, or G6PD, which reduces NADP+ back to NADPH by oxidizing a glucose-6-phosphate.

Glucose-6-phosphate is a metabolite of glucose so we usually have a ready supply of this molecule as long as we are not starving.

Now G6PD deficiency is caused by mutations on the G6PD gene which is found on the X chromosome and thus it’s an X-linked recessive genetic condition and it almost exclusively manifests as a disease in men, since they have one X and one Y chromosome, so if the one and only chromosome has the mutation, then they have the disorder.

Women on the other hand have two X chromosomes, so those with an X chromosome that has the mutation, still have another X chromosome with a normal copy of the gene and thus females are usually carriers and only transmit the disease to their sons.

The G6PD mutations cause defective G6PD enzymes to be produced and these have a shorter half-life, meaning they don’t last as long as the normal enzymes.

There are two common types of G6PD deficiency: a Mediterranean and an African variant.

The Mediterranean variant is characterized by a more markedly reduced half-life of G6PD.

Now, sometimes this can actually be an advantage since it provides protection against falciparum malaria.

G6PD deficiency makes the parasite-infected erythrocyte more susceptible to dying from oxidants, which will also kill the malaria parasites.

So despite the obvious downside to having any of these diseases, they do offer an upside when it comes to warding off a malaria infection.

In fact, because malaria has historically circulated in Africa, the genes underlying these diseases are thought to have conferred a natural selection advantage and therefore became more common in the genetic pool.

Okay, so low levels of G6PD causes low levels of NADPH, leading to low levels of reduced glutathione.

Now G6PD is the only way for red blood cells to get NADPH so they are especially susceptible to damage caused by free radicals.

When these build up, it causes the cell membrane to become unstable, causing their lysis, or hemolysis.

Free radicals can also directly damage hemoglobin molecules which are the oxygen carrying protein in red blood cells.

These damaged proteins precipitates inside the cells and are called Heinz bodies.

The spleen macrophages, that are responsible for eating up old or abnormal red blood cells, notice these Heinz bodies and try to remove them by taking a bite out of the cells, leaving these red blood cells partially devoured, so we call them bite cells.

Now, the good news is that only older red blood cells are at risk for lysis and the hemolytic episode is self-limited as hemolysis stops when only younger red blood cells remain.

Now, when a red blood cell dies, its hemoglobin breaks up into globin and heme.

Heme is converted into bilirubin which is then taken up by the liver cells and eventually secreted out with bile.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Glucose-6-phosphate dehydrogenase deficiency" Best Practice & Research Clinical Haematology (2000)
  7. "Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline" British Journal of Haematology (2020)
  8. "Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline" British Journal of Haematology (2020)